NC
ZYNE

Nexthera Capital’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Nexthera Capital’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-57,100
Closed -$391K – 41
2016
Q2 		$391K Buy
+57,100
New +$478K 0.34% 33
2016
Q1 		– Sell
-15,000
Closed -$151K – 46
2015
Q4 		$151K Buy
+15,000
New +$199K 0.21% 41

Other funds holding ZYNE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
AAM
Auxier Asset Management Aurora, Oregon $696M AUM 18.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nexthera Capital's ZYNE Position: Q3 2016 in Review

Nexthera Capital sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q3 2016, closing a stake of 57,100 shares — an estimated $391K sold.

Nexthera Capital first reported a position in ZYNE in Q4 2015 and held it in 2 quarters. The position peaked at $391K in Q2 2016. 21 funds tracked by Wall St. Rank hold ZYNE as of Q3 2016.

  • Nexthera Capital reported no remaining Zynerba Pharmaceuticals, Inc position as of Q3 2016 after selling out during the quarter.
  • Nexthera Capital sold 57,100 Zynerba Pharmaceuticals, Inc shares in Q3 2016, an estimated $391K.
  • Nexthera Capital first reported a position in Zynerba Pharmaceuticals, Inc in Q4 2015 and held it in 2 quarters.
  • Nexthera Capital's Zynerba Pharmaceuticals, Inc position peaked at $391K in Q2 2016.
  • 21 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q3 2016.

Based on Nexthera Capital's 13F filing for Q3 2016, filed 14 Nov 2016.